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Editors: Anton N. Sidawy and Bruce A. PerlerPerformance of the Aorﬁx endograft in severely angulated
proximal necks in the PYTHAGORAS United States clinical
trial
Mahmoud B. Malas, MD, MHS, William D. Jordan, MD,
Michol A. Cooper, MD, PhD, Umair Qazi, MD, MPH, Adam
W. Beck, MD, Michael Belkin, MD, William Robinson, MD,
and Mark Fillinger, MD
Objective: This study compared the performance of the
Aorﬁx endograft (Lombard Medical, Oxfordshire, United
Kingdom) in standard (<60), highly angled (60-90), and
severely angled (>90) aortic necks in the PYTHAGORAS
study and evaluated changes in neck morphology over time.
Methods: PYTHAGORAS is a prospective nonrandomized
clinical trial of the Aorﬁx endograft. We divided the endo-
vascular aneurysm repair (EVAR) cohort into groups by
standard, high, and severe neck angle. The primary control
group was patients concurrently undergoing open repair.
Mortality at 30 days, 1 year, and 2 years and 30-day freedom
from Society for Vascular Surgerymajor adverse events for the
EVAR groups was compared with the open control. Aneurysm
sac change, type I and III endoleaks, graft migration, and the
reintervention rate at 1 and 2 years was compared between
the standard, highly, and severely angled populations. The
relative risk of graft complications with a neck diameter
increase >10% was also calculated. At predetermined ana-
tomic points, the effect of oversizing on aortic diameter was
evaluated by calculating oversize percentage ([1e outer aortic
diameter measured at a given time/stent graft diameter] 
100%) preoperatively and at 3 years. In addition, the average
oversizing percentage at 30 days and annually at 1 to 5 years
was compared with the preoperative oversizing percentage.
Finally, complication rates with 30% vs <30% planned
oversizing were compared.
Results: The adverse event rate was lower for every EVAR
group than the open control. In addition, the mortality rates
at 30 days, 1 year, and 2 years were similar between the
standard-angle (1.5%, 3.0%, 4.5%), high-angle (0.9%, 7.3%,
13.8%), and severe-angle (4.8%, 9.5%, 14.3%) EVAR groups
and the open control groups (1.3, 6.6%, 10.5%). At 1 and 2
years, there was no difference in graft complications among
the EVAR groups. However, with neck dilatation of >10% at
5 mm above the proximal renal and 1 mm below the distal
renal, there was an increased risk of graft migration (relative
risk, 4.38 [P = .01] and 4.33 [P = .002], respectively). For all
predetermined anatomic points, the oversizing percentage*Full articles available online at www.jvascsurg.org
1078-5884/
http://dx.doi.org/10.1016/S1078-5884(15)00740-6decreased over time. The rate of oversize percentage
decrease was faster at more distal aortic locations, reaching
<10% at 30 days 15 mm below the renal, at 2 years 7 mm
below the renal, and at 5 years 1 mm below the renal (P <
.001 for all). Half the oversize percentage achieved at the
index procedure remained at 3 years (Pearson correlation
coefﬁcient = 0.5). However, there was no difference in
complications between the 30% and <30% planned
oversize groups.
Conclusions: The Aorﬁx endograft has performed well in
excluding aneurysms with standard and highly angled aortic
neck anatomy.Patients with familial abdominal aortic aneurysms are at
increased risk for endoleak and secondary intervention
following elective endovascular aneurysm repair
Evan J. Ryer, MD, Robert P. Garvin, MD, Biju Thomas, MD,
Helena Kuivaniemi, MD, PhD, David P. Franklin, MD, and
James R. Elmore, MD
Objective: A recent investigation has documented an
increased risk of aneurysm-related complications after
endovascular aneurysm repair (EVAR) of familial abdominal
aortic aneurysms (fAAAs). We hypothesized that fAAA
patients are not at increased risk for complications follow-
ing open AAA repair or EVAR when compared with sporadic
abdominal aortic aneurysm (spAAA) patients. To this end,
we performed a single institution retrospective review.
Methods: Epidemiologic data were collected through the
electronic medical record. Family history data were
obtained from a questionnaire administered at the initial
vascular surgery consultation. Major adverse events were
deﬁned as myocardial infarction, respiratory failure, renal
failure, bowel ischemia, limb ischemia, multisystem organ
failure, intracranial hemorrhage, paraplegia, hemorrhage, or
death. Endoleaks were classiﬁed in accordance with the
standardized reporting practices of the Society for Vascular
Surgery. AAA-related complications were deﬁned as the
need for a secondary intervention due to endoleak, limb
ischemia, or postimplantation rupture.
Results: A total of 392 patients with complete clinical data
underwent elective AAA repair from 2004 to 2014. Of these
392 patients, 89 (23%) were classiﬁed as fAAA patients and
303 (77%) were classiﬁed as spAAA patients. With the
exception of increased rates of chronic obstructive pulmo-
nary disease (P = .0009) and pack-years smoked (P = .03) in
spAAA patients, demographics did not differ. Sixty-two
percent (n = 55) of fAAA patients and 68% (n = 205) of
680 AbstractsspAAA patients underwent EVAR (P = .30). fAAA patients
did not incur any signiﬁcant difference in major adverse
events following open AAA repair (fAAA, 9% vs spAAA, 11%;
P = .75). Additionally, fAAA patients did not incur any sig-
niﬁcant difference in major adverse events following EVAR
(fAAA, 4% vs spAAA, 5%; P = .70). Patients with fAAA did
have a signiﬁcantly increased rate of endoleak (fAAA, 24%
vs spAAA, 12%; P = .03) and secondary intervention fol-
lowing EVAR (fAAA, 21% vs spAAA, 12%; P = .04).
Conclusions: The current study shows that patients with
fAAA do not have increased perioperative morbidity fol-
lowing open or endovascular AAA repair. However, patients
with fAAA do have an increased risk of endoleak and sec-
ondary intervention following EVAR. These ﬁndings suggest
that EVAR and open AAA repair are both safe and effective
for fAAA patients. The increased rate of endoleak and sec-
ondary intervention in patients with fAAA suggests that this
subpopulation may beneﬁt from closer post-EVAR surveil-
lance or open surgical repair in good risk patients.Characterizing the evolution of perioperative outcomes
and costs of endovascular abdominal aortic aneurysm
repair
Gregory G. Salzler, MD, Andrew J. Meltzer, MD, Jialin Mao,
MD, MSc, Abby Isaacs, MS, Peter H. Connolly, MD, Darren B.
Schneider, MD, and Art Sedrakyan, MD, PhD
Objective: The purpose of this study is to characterize the
evolution in perioperative outcomes and costs of endo-
vascular abdominal aortic aneurysm (AAA) repair (EVAR) by
detailing changes in adjusted outcomes and costs over time.
Methods: National Inpatient Sample (2000-2011) data were
used to evaluate patient characteristics, outcomes, and
perioperative costs for elective EVAR performed for intact
AAA. Outcomes were adjusted for patient demographics
and comorbidities, and hospital factors by multivariate
analysis. Costs were calculated from hospital cost to charge
ratio ﬁles and adjusted to 2011 dollars.
Results: From 2000 to 2011, 185,249 patients underwent
elective EVAR for intact AAA. The absolute rates of in-hos-
pital major morbidity, mortality, and procedural costs all
decreased signiﬁcantly over time (P < .0001). The preva-
lence of major comorbidities in patients undergoing EVAR,
including obesity, diabetes, and dyslipidemia, all increased
signiﬁcantly over time. After adjusting for multiple demo-
graphics, comorbidities, and hospital-level factors, recent
outcomes of EVAR (2009-2011) remain superior to the early
experience (2000-2002) with respect to mortality and major
complications.
Conclusions: From 2000-2011, the perioperative outcomes
of EVAR improved signiﬁcantly despite a higher prevalence
of comorbidities among patients undergoing repair. Con-
currently, procedure-associated costs declined. Advanced
technology is often implicated in escalating healthcare
spending, and the value of novel techniques is often
questioned. These ﬁndings highlight that, in the case of
EVAR, procedural outcomes have improved while the initialcosts of repair have declined over time. EVAR offers an
interesting example for stakeholders to consider in the era
of cost-containment pressures and criticism of nascent,
expensive technology in healthcare.Contemporary outcomes of lower extremity
revascularization among the hemodialysis-dependent
John M. Fallon, MD, Philip P. Goodney, MD, MS, David H.
Stone, MD, Virendra I. Patel, MD, MPH, Brian W. Nolan, MD,
MS, Jeffrey A. Kalish, MD, Yuanyuan Zhao, MS, and Allen D.
Hamdan, MD, for the Vascular Study Group of New England
Objective: Optimal patient selection for lower extremity
revascularization remains a clinical challenge among the
hemodialysis-dependent (HD). The purpose of this study
was to examine contemporary real world open and endo-
vascular outcomes of HD patients to better facilitate patient
selection for intervention.
Methods: A regional multicenter registry was queried
between 2003 and 2013 for HD patients (N = 689) under-
going open surgical bypass (n = 295) or endovascular
intervention (n = 394) for lower extremity revascularization.
Patient demographics and comorbidities were recorded.
The primary outcome was overall survival. Secondary out-
comes included graft patency, freedom from major adverse
limb events, and amputation-free survival (AFS). Multi-
variate analysis was performed to identify independent risk
factors for death and amputation.
Results: Among the 689 HD patients undergoing lower
extremity revascularization, 66% were male, and 83% were
white. Ninety percent of revascularizations were performed
for critical limb ischemia and 8% for claudication. Overall
survival at 1, 2, and 5 years survival remained low at 60%,
43%, and 21%, respectively. Overall 1- and 2-year AFS was
40% and 17%. Mortality accounted for the primary mode of
failure for both open bypass (78%) and endovascular
interventions (80%) at two years. Survival, AFS, and free-
dom from major adverse limb event outcomes did not differ
signiﬁcantly between revascularization techniques. At 2
years, endovascular patency was higher than open bypass
(76% vs 26%; 95% conﬁdence interval [CI], 0.28-0.71; P =
.02). Multivariate analysis identiﬁed age 80 years (hazard
ratio [HR], 1.9; 95% CI, 1.4-2.5; P < .01), indication of rest
pain or tissue loss (HR, 1.8; 95% CI, 1.3-2.6; P < .01), pre-
operative wheelchair/bedridden status (HR, 1.5; 95% CI,
1.1-2.1; P < .01), coronary artery disease (HR, 1.5; 95% CI,
1.2-1.9; P < .01), and chronic obstructive pulmonary disease
(HR, 1.4; 95% CI, 1.1-1.8; P = .01) as independent predictors
of death. The presence of three or more risk factors resulted
in predicted 1-year mortality of 64%.
Conclusions: Overall survival and AFS among HD patients
remains poor, irrespective of revascularization strategy.
Mortality remains the primary driver for these ﬁndings and
justiﬁes a prudent approach to patient selection. Focus for
improved results should emphasize predictors of survival to
better identify those most likely to beneﬁt from
revascularization.
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stenting with dynamic ﬂow reversal
Christopher J. Kwolek, MD, Michael R. Jaff, DO, J. Ignacio
Leal, MD, L. Nelson Hopkins, MD, Rasesh M. Shah, MD,
Todd M. Hanover, MD, Sumaira Macdonald, MD, and
Richard P. Cambria, MD
Objective: This report presents the 30-day results of the
Safety and Efﬁcacy Study for Reverse Flow Used During
Carotid Artery Stenting Procedure (ROADSTER) multicenter
trial and evaluates the safety and efﬁcacy of ENROUTE
Transcarotid NPS (Silk Road Medical Inc, Sunnyvale, Calif), a
novel transcarotid neuroprotection system that provides
direct surgical common carotid access and cerebral embolic
protection via high-rate ﬂow reversal during carotid artery
stenting (CAS).
Methods: A prospective, single-arm, multicenter clinical
trial was performed to evaluate the use of the ENROUTE
Transcarotid NPS during CAS procedures performed in
patients considered to be at high risk for complications
from carotid endarterectomy. Symptomatic patients with
50% stenosis and asymptomatic patients with 70%
stenosis were eligible to be treated with any U.S. Food and
Drug Administration-approved carotid artery stent. The
primary end point was the composite of all stroke, myo-
cardial infarction (MI), and death at 30 days postprocedure
as deﬁned in the Food and Drug Administration-approved
study protocol. Secondary end points included cranial nerve
injury; 30-day stroke, death, stroke/death, and MI; acute
device, technical, and procedural success; and access site
complications. All major adverse events were adjudicated
by an independent clinical events committee.
Results: Between November 2012 and July 2014, 208
patients were enrolled at 18 sites. Sixty-seven patients were
enrolled as lead-in cases, and 141 were enrolled in the
pivotal phase. In the pivotal cohort, 26% were symptomatic
and 75% were asymptomatic. Acute device and technical
success were 99% (140 of 141). By hierarchical analysis, the
all-stroke rate in the pivotal group was 1.4% (2 of 141),
stroke and death was 2.8% (4 of 141), and stroke, death and
MI was 3.5% (5 of 141). One patient (0.7%) experienced
postoperative hoarseness from potential Xth cranial nerve
injury, which completely resolved at the 6-month follow-up
visit.
Conclusions: The results of the ROADSTER trial demonstrate
that the use of the ENROUTE Transcarotid NPS is safe and
effective at preventing stroke during CAS. The overall strokerate of 1.4% is the lowest reported to date for any pro-
spective, multicenter clinical trial of CAS.Cost analysis of vascular readmissions after common
vascular procedures
Nathan T. Orr, MD, Shady El-Maraghi, BSc, Ryan L. Korosec,
CPA, MBA, Daniel L. Davenport, PhD, and Eleftherios S.
Xenos, MD, PhD
Objective: This study analyzed readmissions and their
associated hospital costs after common vascular surgeries at
a single institution.
Methods: Patients undergoing open or endovascular
abdominal aortic aneurysm repair, aortoiliac revasculariza-
tion, or infrainguinal revascularization, from 2010 through
2012, were retrospectively evaluated. We compared 30-
and 90-day readmission rates and costs by procedure group,
and we tabulated reasons for readmission and procedures
performed during readmission. We used both American
College of Surgeons National Surgical Quality Improvement
Program (ACS NSQIP) data and patient records; as NSQIP
only captures 30-day data, we retrospectively reviewed
patient charts to extend the evaluation to 90 days. Analyses
were performed using parametric or nonparametric meth-
ods as appropriate.
Results: Two hundred nineteen cases were analyzed; the
overall rate of index admission survivors experiencing at
least one readmission within 30 days was 17% and within
90 days, 27%. Median readmission costs were $10,700,
which added 39% to the median index costs of $27,700.
Over half of readmissions (55%) included an operation. The
most common cause for readmission was related to wound
complications, comprising approximately 30% of the entire
readmission cohort. Independent drivers of readmission
costs were the need for additional surgical procedures, the
use of intensive care unit services, and the number of days
spent in the hospital above the median. Total 90-day costs
were statistically equivalent between open and endovas-
cular procedures when including readmissions.
Conclusions: We found that vascular surgery readmissions
occur at a rate of 17% at 30 days and 27% at 90 days. When
including the costs of readmission for a wide variety of
common vascular cases, there is no signiﬁcant difference in
total costs between endovascular and open procedures at
90 days.
